Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Aktiespararna's Aktiedagen Stockholm 2022
23 slides from Expres2ion Biotech Holding Ab's conference presentation, Mar 14, 2022
Slide 1: Proteins for Life
Aktiespararna’s Aktiedagen Stockholm - Virtual March 14, 2022 Proteins for Life Bent U. Frandsen, CEO
Slide 2: Disclaimer
Disclaimer This company presentation (the ”Company Presentation”), which is personal to the recipient, is issued by ExpreS2ion Biotech Holding AB (the “Company”). The Company Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of
Slide 3: Investment Highlights
Investment Highlights Key player in advanced protein sciences, with deep pipeline of novel vaccines addressing high- value markets High-potential pipeline of key focus, backed up by Contract Research Organization (CRO) business, that has generated SEK 60 million since IPO in 2016 Vaccine development
Slide 4: Technology Platforms
Technology Platforms ExpreS2ion’s ExpreS2 and AdaptVac’s cVLP platform Particle (VLP) technology AdaptVac’s proprietary virus-like particles (VLP) technology Cell line derived from Drosophila melanogaster securely attaches our proteins to (fruit fly) S2 cells1 the surface of a capsid (outer protein
Slide 5: ExpreS2 and AdaptVac's VLP
2 ExpreS and AdaptVac’s VLP The platforms combined enable powerful vaccines to handle a wide range of diseases ExpreS2, advantages in discovery manufacturing AdaptVac’s cVLP platform, high immunogenic potential ✓ Rapid delivery (3-6 months) of high-quality and uniform ✓ Full length proteins: Excepti
Slide 6: Deep Pipeline for Value Creation
Deep Pipeline for Value Creation Development Progress Pre-clinical DISEASE Project/Target Discovery cGMP / Tox Phase I Phase II Phase III Partner/Funding Pharmacology Phase III Coronavirus ABNCoV2/SARS-CoV-2cVLP ABNCoV2/SARS-CoV-2 cVLP I / II initiation: H1 2022 PREVENT-nCoV Phase I 100% Breast Canc
Slide 7: Our Programs
Our Programs Proteins for Life
Slide 8: The 2nd Generation COVID-19 Vaccine
CORONAVIRUS nd The 2 Generation COVID-19 Vaccine With over 6 million deaths worldwide1, significant needs remain in the global long-term fight against the SARS-CoV-2 virus: Uncertain duration of effect with current vaccines, expected to need repeated boosters Storage and handling requirements for ma
Slide 9: ABNCoV2 COVID-19 Vaccine (I)
CORONAVIRUS ABNCoV2 COVID-19 Vaccine (I) Phase I/IIa study confirms safety and tolerability and excellent efficacy profile ABNCoV2 induces high neutralization High virus neutralization levels were antibody titers shown across COVID-19 variants • Dose response: increased titers with higher vaccine do
Slide 10: ABNCoV2 COVID-19 Vaccine (II)
CORONAVIRUS ABNCoV2 COVID-19 Vaccine (II) Phase II study show high levels of neutralizing antibodies across all study groups Highly efficacious against SARS-CoV-2 Strong booster response for both 50μg and 100μg doses • In both primary and booster vaccination, ABNCoV2 increased levels 100 μg 50 μg of
Slide 11: ABNCoV2 COVID-19 Vaccine (III)
CORONAVIRUS ABNCoV2 COVID-19 Vaccine (III) Bavarian Nordic plan phase III study initiation H1 2022, granted DKK 800m funding Seronegative antibody titers confirms phase I results Initiation of phase III in H1 2022 • An overall agreement has been made with regulatory authorities on the trial design •
Slide 12: Partnership with Bavarian Nordic
CORONAVIRUS Partnership with Bavarian Nordic ABNCoV2 is already out-licensed with near-term revenue streams supporting ExpreS2ion AdaptVac receive from Bavarian Nordic ExpreS2ion receive from AdaptVac • EUR 4 million upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to EUR 136 million in
Slide 13: Breast Cancer Overview
BREAST CANCER Breast Cancer Overview The ES2B-C001 vaccine can offer significant benefits compared to current treatment options Monoclonal antibodies are the cornerstone of treatment Serious drawbacks exist with these therapies2 for HER2+ breast cancer (>USD 11bn sales)1 • Resistance to monoclonal a
Slide 14: ES2B-C001 Overcomes Herceptin Resistance
BREAST CANCER ES2B-C001 Overcomes Herceptin Resistance The soft agar human cancer cell growth inhibition assay provides in vitro evidence UNTREATED ES2B-C001 Trastuzumab- sensitive HER2+ human cancer cells1 Both Herceptin (trastuzumab) and ES2B-C001 inhibited growth in the trastuzumab-sensitive cell
Slide 15: ES2B-C001 Preclinical Proof-of-Concept
BREAST CANCER ES2B-C001 Preclinical Proof-of-Concept ES2B-C001 has demonstrated animal proof-of-concept Effectively inhibited tumor development Prevented tumor development with 95% efficiency Tumor growth in FVB mice (HER2-intolerant) ES2B-C001 with adjuvant (n=20) Control (n = 10) Untreated (n=26)
Slide 16: Financials and Outlook
Financials and Outlook Proteins for Life
Slide 17: Financials – Fitting the New Strategy
Financials – Fitting the New Strategy Revenues, SEK ‘000s Operating costs, SEK ‘000s Cash balance1, SEK million 6.000 160 0 142 139 5.000 140 -3.000 4.000 120 107 108 3.000 -6.000 100 83 2.000 -9.000 80 1.000 -12.000 60 0 -15.000 40 30 -18.000 20 13 Net sales Other operating income 10 5 3 5 6 -21.00
Slide 18: Advancing Towards Key Catalysts
Advancing Towards Key Catalysts 2022 2023 2024 CORONAVIRUS (ABNCoV2) BN Phase II BN Phase II BN Phase III BN Phase III BN ready for study initiation study readout study initiation initial readout market launch (Q3’21) H1 2022 H1 2022 H2 2022 (subject to regulatory approval) BREAST CANCER (ES2B-C001)
Slide 19: Thank you!
Thank you! Contact: info@expreS2ionbio.com Proteins for Life
Slide 20: ExpreS2ion's Business Model
2 ExpreS ion’s Business Model High-potential pipeline and revenue generating CRO business ExpreS2 Platform for Protein Expression +500 different proteins have been produced with the ExpreS2 platform, while posting a success rate exceeding 90% across +100 clients and partners. Novel Pipeline Developm
Slide 21: Experienced Board and Management
Experienced Board and Management Proteins for Life
Slide 22: Management Team
Management Team Experienced team driving pipeline-focused business Bent U. Frandsen, CEO Dr. Mette Thorn, VP Preclinical Development • MSc. In Finance/Strategic Management, Copenhagen Business School, • PhD in Immunology, and a MSc in Chem Eng., Tech. Univ of Denmark Denmark • 20 years industrial re
Slide 23: Board of Directors
Board of Directors Expanded the Board in 2021 in support of the transition to a pipeline-focused business Dr. Martin Roland Jensen, Chairman Dr. Karin Garre, Board Member • PhD. in Molecular and Cell Biology, Univ. of Copenhagen, Denmark • MD, from University of Copenhagen, Denmark • >35 years biote
ExpreS2ion Biotech Holding — Aktiespararna's Aktiedagen Stockholm 2022 on 6ix